Taglich Brothers Initiates Coverage with Speculative Buy Recommendation on Apricus Biosciences - Video Research Alert on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - February 20, 2015) - Taglich Brothers has initiated coverage on Apricus Biosciences (NASDAQ: APRI). Analyst Juan Noble gives the company a speculative buy rating, and a 12 month price target of $5.80, a premium of 210% to the $1.87 price on February 18th, the day the report was issued.

InvestmentPitch.com has produced a "video research alert" about Apricus Biosciences based on this report. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Apricus" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_22rjn65a/Taglich-Brothers-has-initiated-coverage-on-Apricus-Biosciences-NASDAQ-APRI

Apricus Biosciences is a biopharmaceutical company advancing innovative medicines in urology and rheumatology.

The company's lead product, Vitaros, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. Vitaros, a topical treatment, should be a strong competitor, as it is proven effective and safe, and is far easier to administer than competing formulations.

The company has a strong network of strategic partners, including Abbott Labs, agreements with which will earn double-digit royalties, revenue based milestone payments, and manufacturing revenue.

Analyst Juan Noble stated: "By our estimates, the overseas erectile dysfunction patient population that should be targeted by Vitaros is around nine million. Modest penetration of Vitaros' target market could, in our view, generate $150 million in revenue by 2020."

Pipeline products that treat testosterone deficiency, rheumatic diseases and female arousal disorders offer longer term revenue potential.

At the end of the 3rd quarter, the company had $16 million in cash but is likely to need substantial additional financing as revenue gains create a larger need for working capital.

The company currently trades at $2.00, well below the $5.80 target price, and with 43.6 million shares outstanding, the company is capitalized at $87 million.

For more information please visit the company's website www.apricusbio.com.

Investor relations for retail investors is handled by Chris Eddy at Catalyst Global, who can be reached at 212-924-9800 or email apri@catalyst-ir.com.

Institutional investors should contact Angeli Kolhatkar at Arecia Advisors, who can be reached at 917-387-4770 or email angeli@areciaadvisors.com.

For more information about Taglich Brothers or to obtain a copy of their extensive research report, please visit the company's website www.taglichbrothers.com.

About InvestmentPitch

InvestmentPitch.com is a leading international producer and distributer of specialized video content for the investment community. The company specializes in producing three minute videos based on news releases, research reports and other news of interest to investors.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com